Asta Bio
Reimagining Cancer Treatment with Targeted Radiotherapy
Asta Bio is a company in therapeutics based in United States, founded in 2024.
Profile
Our technology combines 211-Astatine, the most druggable alpha-emitting radioisotope, with multivalent single-domain antibodies to deliver potent alpha radiation that breaks DNA strands and kills the tumor cells while leaving normal cells unaffected.
Asta Bio is positioned in therapeutics, a segment that rewards a clear, focused offering.
The company is recorded as being based in United States.
Its current recorded stage is SOSV portfolio company.
The company reports a headcount in the 2-10 range.
Public records show total funding of about $45K.
| Sector | Therapeutics |
|---|---|
| Country | United States |
| Founded | 2024 |
| Employees | 2-10 |
| Stage | SOSV portfolio company |
| Total funding | $450,000 |
Website: www.astabiotx.com
Full contact details are available to registered Pixilab members.
Create a free account
Create a free account